Within the long story of how human bodies build the molecules they need, a small gene called PSPH has quietly carried a history of its own. Researchers now looking back through ancient genomes have found that the versions carried by early hunter-gatherers worked differently from the one most people carry today, and that disease-linked versions worked least of all. The enzyme at the center of this story helps make L-serine, an amino acid whose shortage is tied to disorders of the developing nervous system. What the study reveals so far is a measurable gradient of function across time and variat
Ancient Human PSPH Gene Variants Show Reduced Function Compared With Modern Versions, Study Finds
Modern human PSPH worked best; ancient versions less so; disease variants least
Mark
So what's the basic finding here?
Mimi
Three versions of the same enzyme, ranked. Modern human PSPH worked best in the yeast tests, ancient hunter-gatherer versions worked less well, and disease-linked variants worked worst.
Mark
And why does that enzyme matter?
Mimi
It's needed to make L-serine. When certain variants cut that supply, the nervous system suffers.
Luke
Before we get carried away: 'diminished function' in yeast is not the same as a deficit in an ancient person. Do we know the ancient variants caused any problem?
Mimi
No. The source doesn't say that. It reports lower enzyme function in the assay, nothing about the health of the people who carried them.
Mark
So what's the real contribution?
Mimi
DeLuna describes it as a method: using evolution to pick which variants to test, then running them in a scalable yeast system. It can surface differences that would otherwise go unnoticed.
Luke
Worth noting that's the author's own assessment of his approach. Whether it works on other genes is untested here.
Mark
Any clinical angle?
Luke
Not established in what we've been given. It's a lab result about enzyme activity, and the leap to treatment would be a separate question.
O Pulso
- A single gene's enzyme is caught between ancient and modern forms, and its output is measurably shifting.
- Disease-linked PSPH variants show the weakest enzyme activity, sitting at the edge of a nervous system risk.
- Researchers are using evolutionary history to choose which variants to test, a method that could expose hidden differences.
- The work runs in yeast rather than patients, so the trajectory points toward new questions, not yet toward clinical answers.
Within the long story of how human bodies build the molecules they need, a small gene called PSPH has quietly carried a history of its own. Researchers now looking back through ancient genomes have found that the versions carried by early hunter-gatherers worked differently from the one most people carry today, and that disease-linked versions worked least of all. The enzyme at the center of this story helps make L-serine, an amino acid whose shortage is tied to disorders of the developing nervous system. What the study reveals so far is a measurable gradient of function across time and variation, not yet a map of what those differences meant for lives lived in the past or for patients today.
A gene that helps the body build one amino acid has a deeper past than anyone expected, and that past is visible in how well its enzyme performs. A new study in FEBS Open Bio compares versions of the PSPH gene recovered from ancient human genomes with the modern human sequence and with variants linked to disease. The gene encodes phosphoserine phosphatase, an enzyme needed to make L-serine, and when certain variants prevent the body from making enough of it, nervous system problems follow. That connection is why PSPH is associated with neurodevelopmental conditions.
The researchers found that the ancient hunter-gatherer sequences differ from the modern one, and the difference is not only genetic lettering. It shows up in function. Using evolution-guided yeast complementation assays, in which the human enzyme is set to work inside yeast, the team measured how well each version did its job. Modern human phosphoserine phosphatase performed best, the ancient versions performed less well, and the disease-associated variants performed worst.
Co-corresponding author Alexander DeLuna of CINVESTAV in Mexico emphasized the method. Pairing evolution-guided choice of variants with scalable assays in another organism, he said, can reveal functional differences that standard approaches might miss. The study does not say what the ancient variants meant for the people who carried them, and it offers no clinical application, since it rests on yeast experiments rather than patient studies. What it does establish is a clear gradient of enzyme activity across ancient, modern and disease-linked forms. The open question is whether this evolutionary lens will uncover overlooked functional differences in other genes.
A gene that helps the body build one amino acid turns out to have a deep history, and that history shows up in how well its enzyme works. New research in FEBS Open Bio compares versions of the PSPH gene found in ancient human genomes with the modern human sequence and with variants tied to disease.
PSPH encodes an enzyme called phosphoserine phosphatase. The enzyme is needed to make L-serine. Certain variants of the gene keep the body from producing enough of that amino acid, and the result is a range of nervous system problems. That link is why the gene is associated with neurodevelopmental conditions.
The investigators found that the modern human DNA sequence of PSPH is not the same as the sequences identified in ancient hunter-gatherers. The difference is more than a matter of letters on a page. It also shows up in function.
To test this, the team used evolution-guided yeast complementation assays. In this kind of experiment, the human version of the enzyme is put to work in yeast, so researchers can see how well it does the job. The results fell into a clear order. Modern-day human phosphoserine phosphatase had the greatest functionality. The ancient proteins showed diminished function. The disease-associated variants had the weakest function of all.
Co-corresponding author Alexander DeLuna, Ph.D., of the Center for Research and Advanced Studies (CINVESTAV) in Mexico, framed the work as a point about method. He said the study highlights the potential of pairing evolution-guided prioritization of variants with scalable assays run in a different host organism. Such a combination, he said, can uncover functional differences that might otherwise be overlooked.
The source does not say what the ancient variants meant for the people who carried them, and it does not describe any clinical application. The findings come from yeast assays of enzyme function, not from studies of patients. What the work does establish is a measured gradient in enzyme activity across ancient, modern and disease-linked forms of the same gene.
What to watch for is whether the same approach, which looks to evolutionary history to decide which variants to test, turns up overlooked functional differences in other genes. The paper is titled "Evolution-guided yeast complementation reveals functional differences in human PSPH variants" (DOI: 10.1002/2211-5463.70308).
Citações Notáveis
The study highlights the potential of combining evolution-guided variant prioritization with scalable heterologous assays to uncover functional differences that may otherwise be overlooked.— Alexander DeLuna, Ph.D., CINVESTAV, co-corresponding author
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Science & Space